A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) Plus Ritonavir (100mg BID) Versus Lopinavir/Ritonavir (400mg/100mg BID) When Administered in Combination With the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks.

Trial Profile

A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) Plus Ritonavir (100mg BID) Versus Lopinavir/Ritonavir (400mg/100mg BID) When Administered in Combination With the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Fosamprenavir; Lamivudine/abacavir; Lopinavir/ritonavir; Ritonavir
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KLEAN
  • Most Recent Events

    • 24 Mar 2009 Additional locations Luxembourg, Romania, Spain reported by ClinicalTrials.gov.
    • 25 Oct 2008 144-week results were reported at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America - A Joint Meeting.
    • 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top